Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS

Journal of the American Academy of Dermatology

Volumn 47, Issue 1, 2002, Pages 40-46

  Eliaszewicz, Muriel ^a   Flahault, Antoine ^d   Roujeau, Jean Claude ^e   Fillet, Anne Marie ^b   Challine, Dominique ^e   Mansouri, Samira ^d   Wolkenstein, Pierre ^e   Aractingi, Sélim ^d   Penso Assathiany, Dominique ^f   Maslo, Caroline ^c   Bourgault Villada, Isabelle ^g   Chosidow, Olivier ^b   Caumes, Eric ^b  

^a INSTITUT PASTEUR   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL ROTHSCHILD   (France)

^d HÔPITAL TENON   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f BICÊTRE HOSPITAL   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; GLUTATHIONE PEROXIDASE; PYRIMETHAMINE; SULFADIAZINE; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DISEASE MARKER; DRUG ACETYLATION; DRUG ERUPTION; EPSTEIN BARR VIRUS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARVOVIRUS; PATHOGENESIS; PHENOTYPE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK FACTOR; SKIN MANIFESTATION; T LYMPHOCYTE SUBPOPULATION; TOXOPLASMOSIS; VIRUS REPLICATION;

EID: 0036658276     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120468     Document Type: Article

References (28)

1. Coopman S, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328: 1670-4.
2. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensibilization to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1995;9:573-5.
3. Hennesy S, Strom BL, Berlin JA, Brennan PJ. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med 1995;10:380-6.
4. Carr A, Tindall B, Penny R, Cooper DA. Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993;7:1532-3.
5. Kennedy CA, Pimentel JA, Lewis DE, Anderson MD, Weiss PJ, Oldfield EC III. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. J Infect Dis 1993;168:314-7.
6. Veenstra J, Veugelers PJ, Keet IPM, van der ven AJ, Miedema F, Lange JM, et al. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis 1997;24:936-41.
7. Smith KJ, Skelton HG, Yeager J, Ledsky R, Ng T-H, Wagner KF. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol 1997;22:118-23.
8. Carr A, Swanson C, Penny R, Cooper DA, Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993;167:180-5.
9. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1994;8:333-7.
10. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, et al. Systemic glutathione deficiency in symptom-free HIV sero-positive individuals. Lancet 1989;334:1294-8.
11. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;116:33-43.
12. Caumes E, Roudier C, Rogeaux O, Bricaire F, Gentilini M. Effects of corticosteroids on the incidence of adverse reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia. Clin Infect Dis 1994; 18:319-23.
13. Walmsley S, Levinton C, Brunton J, Muradali D, Rappaport D, Bast M, et al. A multicenter randomized double-blind placebo controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr 1995; 8:348-57.
14. Chosidow O, Bourgault I, Roujeau JC. Drug rashes. What are the targets of cell-mediated cytotoxicity? Arch Dermatol 1994;130: 627-9.
15. Wolkenstein P, Loriot M, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulfonamides in AIDS. Pharmacogenetics 2000;10:821-8.
16. Gautheret A, Aubin JT, Poirel L, Chopineau S, Agut H, Dussaix E. Detection and variant identification of HHV 6 by a non radioactive hybridization microplate assay for amplimers detection. J Virol Med 1996;58:33-40.
17. Aubin JT, Poirel L, Robert C, Huraux JM, Agut H. Identification of human herpesvirus 6 variants A and B by amplimer hybridization with variant-specific oligonucleotides and amplification with variant-specific primers. J Clin Microbiol 1994;32:2434-40.
18. Simpson GR, Schulz TF, Whitby D, Cook PM, Rainbow L, Howard MR, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996;348: 1133-8.
19. Caumes E. Cutaneous adverse reactions and CD4+ cell counts in human immunodeficiency virus infected patients receiving trimethoprime-sulfamethoxazole [letter]. Clin Infect Dis 1998; 26:530-1.
20. Van der Ven AJAM, Koopmans PP, Vree TB, Van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991;338:431-3.
21. Pirmohamed M, Williams D, Tingle MD, Barry M, Khoo SH, O'Mahony C, et al. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996;10:501-7.
22. Akerlund B, Tynell E, Bratt G, Bielenstein M, Lidman C. N-acetyl-cystein treatment and the risk of toxic reactions to trimethoprim-sulfamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. J Infect 1997;35:143-7.
23. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-35.
24. Deloménie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, et al. Acetylation genotype and risk of severe reactions to sulfonamides in AIDS patients. Br J Clin Pharmacol 1994;38:581-2.
25. Podzamzer D, Consiglio E, Ferrer E, Gudiol F. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS 2000;14:331-2.
26. Caumes E, Bocquet H, Guermonprez G, Rogeaux O, Bricaire F, Katlama C, et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis 1995;21:656-8.
27. Iborra C, Jouan M, Baril L, Katlama C, Bricaire F, Caumes E. Highdose trimethoprim-sulfamethoxazole therapy with corticosteroids in previously-intolerant patients with AIDS-associated Pneumocystis carinii pneumonia. Arch Dermatol 1999;135:350-1.
28. Rey D, Partisani M, Krantz V, Kempf G, Nicolle M, de Mautort E, et al. Prednisolone does not prevent the occurrence of nevirapine-induced rashes [letter]. AIDS 1999;13:2307.